JP2014515354A - Ｏｓｗ−１類似体および抱合体、ならびにそれらの使用 - Google Patents

Ｏｓｗ−１類似体および抱合体、ならびにそれらの使用 Download PDF

Info

Publication number
JP2014515354A
JP2014515354A JP2014511580A JP2014511580A JP2014515354A JP 2014515354 A JP2014515354 A JP 2014515354A JP 2014511580 A JP2014511580 A JP 2014511580A JP 2014511580 A JP2014511580 A JP 2014511580A JP 2014515354 A JP2014515354 A JP 2014515354A
Authority
JP
Japan
Prior art keywords
certain embodiments
group
compound according
aforementioned compounds
osbp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014511580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515354A5 (enExample
Inventor
シェア，マシュー，ディー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2014515354A publication Critical patent/JP2014515354A/ja
Publication of JP2014515354A5 publication Critical patent/JP2014515354A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2014511580A 2011-05-19 2012-05-18 Ｏｓｗ−１類似体および抱合体、ならびにそれらの使用 Pending JP2014515354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488023P 2011-05-19 2011-05-19
US61/488,023 2011-05-19
PCT/US2012/038562 WO2012159027A2 (en) 2011-05-19 2012-05-18 Osw-1 analogs and conjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2014515354A true JP2014515354A (ja) 2014-06-30
JP2014515354A5 JP2014515354A5 (enExample) 2015-07-09

Family

ID=47177654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511580A Pending JP2014515354A (ja) 2011-05-19 2012-05-18 Ｏｓｗ−１類似体および抱合体、ならびにそれらの使用

Country Status (5)

Country Link
US (1) US9790253B2 (enExample)
EP (1) EP2710024A4 (enExample)
JP (1) JP2014515354A (enExample)
CN (1) CN103857689A (enExample)
WO (1) WO2012159027A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056236A (zh) * 2015-08-13 2015-11-18 暨南大学 Orp4l在制备治疗急性髓性白血病产品中的应用
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN111159770B (zh) * 2019-12-31 2022-12-13 医渡云（北京）技术有限公司 文本数据脱敏方法、装置、介质及电子设备
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
FR3125047B1 (fr) * 2021-07-06 2024-03-15 Centre Nat Rech Scient Composé de type 7a,8,9,10,11,11a-hexahydro-1H,7H-pyrano[2,3-c]xanthene, leur procédé de préparation, leurs intermédiaires et leurs applications thérapeutiques.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0948794A (ja) * 1995-06-02 1997-02-18 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
US20030069214A1 (en) * 2001-08-07 2003-04-10 Zhendong Jin Process for preparing saponin compounds
CN1844138A (zh) * 2006-05-12 2006-10-11 中国科学院上海有机化学研究所 一种合成虎眼万年青皂甙的脱除保护基的方法
WO2010068877A2 (en) * 2008-12-11 2010-06-17 President And Fellows Of Harvard College Compounds that bind oxysterol binding proteins, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318924A1 (de) 1993-06-03 1994-12-08 Schering Ag Cephalostatin-Analoga
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
WO2004091484A2 (en) * 2003-04-07 2004-10-28 Board Of Regents, The University Of Texas System Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en­22-one 16-0-(2-0-4-methoxybenzoyl-beta-d-xylopyranosyl)-(1->3)-(2-0­acetyl-alpha-l-arabinopyranoside)] or osw-1 and its derivatives for cancer therapeutics
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
AU2005227328A1 (en) 2004-03-29 2005-10-06 John A. Beutler Schweinfurthin analogues

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0948794A (ja) * 1995-06-02 1997-02-18 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
US20030069214A1 (en) * 2001-08-07 2003-04-10 Zhendong Jin Process for preparing saponin compounds
CN1844138A (zh) * 2006-05-12 2006-10-11 中国科学院上海有机化学研究所 一种合成虎眼万年青皂甙的脱除保护基的方法
WO2010068877A2 (en) * 2008-12-11 2010-06-17 President And Fellows Of Harvard College Compounds that bind oxysterol binding proteins, and methods of use thereof

Also Published As

Publication number Publication date
CN103857689A (zh) 2014-06-11
US9790253B2 (en) 2017-10-17
EP2710024A2 (en) 2014-03-26
US20140135279A1 (en) 2014-05-15
WO2012159027A2 (en) 2012-11-22
WO2012159027A3 (en) 2013-03-28
EP2710024A4 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
AU2021269433A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
KR102692309B1 (ko) Fxr (nr1h4) 조정 화합물
JP6300730B2 (ja) ベツリンの誘導体
JP7021080B2 (ja) ファルネソイドｘ受容体調節剤
US9790253B2 (en) OSW-1 analogs and conjugates, and uses thereof
KR20190017027A (ko) Fxr (nr1h4) 조정 화합물
CN104910238B (zh) 一类五环三萜类化合物及其在制备治疗阿尔兹海默病的药物中的用途
CN100526328C (zh) 17β-羟基类固醇脱氢酶抑制剂
WO2012013816A1 (en) Compounds and methods for treating neoplasia
CA3022327C (en) INDAZOLE SYNTHESIS
EP2499151A2 (en) Mammalian metabolites of steroids
Fan et al. Design, synthesis, and biological evaluation of a novel indoleamine 2, 3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
CN115715201A (zh) 葡萄糖雷公藤甲素缀合物及其用途
Li et al. Synthesis and discovery of mitochondria-targeting oleanolic acid derivatives for potential PI3K inhibition
CN111630047A (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
Pettit et al. Antineoplastic agents. 606. The betulastatins
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2019196953A1 (en) Ntcp inhibitors
NL2031175B1 (en) Dhcr24 inhibitory compounds
CN120513097A (zh) 订书钉化肽及其方法
ES2312965T3 (es) Sulfamatos de d-homoestra-1,3,5(10)-trien-3-il-2-sustituidos con efectos antitumoral.
US20110319352A1 (en) Compounds That Bind Oxysterol Binding Proteins, and Methods of Use Thereof
Nunez The Ligand Binding Properties of the Oxysterol-binding Protein Family Subfamily-I
Dormann Synthetic Studies on Small Molecule Src Homology 2 Domain Containing Inositol 5’Phosphatase (SHIP) Modulators and Studies Towards the Design and Synthesis of a SHIP PROTAC
KR20240125979A (ko) 에폭시 스테로이드

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170328